PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

Antibody drug conjugates (ADCs) have become an important modality of clinical cancer treatment. However, traditional ADCs have some limitations, such as reduced permeability in solid tumors due to the high molecular weight of monoclonal antibodies, difficulty in preparation and heterogeneity of prod...

Full description

Bibliographic Details
Main Authors: Qiyu Li, Wenjing Li, Keyuan Xu, Yutong Xing, Haobo Shi, Zhe Jing, Shuang Li, Zhangyong Hong
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:International Journal of Molecular Sciences
Subjects:
HER2
affibody
antibody drug conjugates (ADCs)
MMAE
Online Access:https://www.mdpi.com/1422-0067/22/4/1540

Similar Items

Similar Items